Mat2Rep is an industrial research project approved on the “Call for strategic industrial research projects aimed at the priority areas of the smart specialization strategy” (DGR 986/2018) within the POR-FESR EMILIA ROMAGNA 2014-2020, Axis 1 – Research and innovation, Action 1.2.2
IRET FOUNDATION – Leading partner
MISTER – Industrial research laboratory
UNIBO CIRI-SDV – Industrial research laboratory
ISTEC CNR – Industrial research laboratory
UNIMORE DSV – Industrial research laboratory
Transmed Research Srl
Chiesi Farmaceutici Spa
Finceramica Faenza SpA
Mat2Rep will develop 4 products for reparative medicine, aimed to recruit stem cells and endogenous precursors and to control inflammation and tissue hypoxia. Mat2Rep will combine biomaterials and drugs already on the market to optimize a polypharmacy of orphan therapy conditions or whose therapy is unsatisfactory. The pivotal pathologies on which the new technological solutions will be tested relate to injuries and pathologies that are particularly disabling for the central nervous system (acute phase of traumatic vascular lesions) and the skin (chronic ulcers). Mat2Rep will have a strong meaning for the field of disability.
The project aims to respond to specific “medical needs”: (i) therapy of “orphan” conditions, such as the acute phase of traumatic CNS injuries; (ii) highly invalidating conditions therapy improvement, such as infantile cerebral palsy; (iii) improvement of the treatment of conditions with a strong social and economic impact, such as chronic ulcers.
The objective of the project will be declined on 4 expected results to lead to preclinical testing, carried out starting from drugs already on the market and electroconducting biomaterials.
At the end of the project, 4 new products are expected to be validated for preclinical efficacy, 2 for CNS reparative medicine, 2 for skin, the latter also for veterinary medicine.